Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest

Radiotherapy and Oncology

Volumn 115, Issue 1, 2015, Pages 120-127

  Kriegs, Malte ^a   Gurtner, Kristin ^c   Can, Yildiz ^a   Brammer, Ingo ^a   Rieckmann, Thorsten ^a   Oertel, Reinhard ^d   Wysocki, Marek ^c   Dorniok, Franziska ^c   Gal, Andreas ^b   Grob, Tobias J ^b   Laban, Simon ^a   Kasten Pisula, Ulla ^a   Petersen, Cordula ^a   Baumann, Michael ^c,e,f   Krause, Mechthild ^c,e,f   Dikomey, Ekkehard ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Human Genetics ^*  (Germany)

^c Helmholtz Zentrum Dresden Rossendorf   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f Hemholtz Zentrum Dresden Rossendorf   (Germany)

Author keywords

Cell cycle; EGFR inhibition; G1 arrest; NSCLC; p53; Radiosensitization

Indexed keywords

CETUXIMAB; DEMECOLCINE; DIMETHYL SULFOXIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FALNIDAMOL; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SIZE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL KINETICS; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IRRADIATION; LUNG CANCER CELL LINE; MASS SPECTROMETRY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; DRUG EFFECTS; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL LINE, TUMOR; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; QUINAZOLINES; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930763074     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.02.018     Document Type: Article

References (41)

1. M.D. Marmor, K.B. Skaria, and Y. Yarden Signal transduction and oncogenesis by ErbB/HER receptors Int J Radiat Oncol Biol Phys 58 2004 903 913
2. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
3. K.K. Ang Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 2002 7350 7356
4. U. Kasten-Pisula Cellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without EGFR amplification Int J Radiat Oncol Biol Phys 80 2011 1181 1188
5. S.V. Sharma Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
6. J.A. Bonner Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2010 21 28
7. J.G. Eriksen DAHANCA19: a randomized phase III study of primary (chemo-)radiotherapy and zalutumumab in head and neck carcinomas Radiother Oncol 111 2014 154
8. European-Medicines-Agency. Tarceva: EPAR - Summary for the public. 2011 09-2011 [cited 2014 21.10.2014]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001016/human-med-000857.jsp&mid=WC0b01ac058001d124.
9. B. Center A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer J Thorac Oncol 5 2010 69 74
10. V.K. Mehta Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence Front Oncol 2 2012 31
11. S. Rothschild Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial Int J Radiat Oncol Biol Phys 80 2011 126 132
12. J. Wang Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer Int J Radiat Oncol Biol Phys 81 2011 e59 e65
13. C.C. Chang Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience Lung cancer 73 2011 189 194
14. N. Ready Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial J Thorac Oncol 5 2010 1382 1390
15. K. Dittmann, C. Mayer, and H.P. Rodemann Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity Radiother Oncol 76 2005 157 161
16. M. Toulany Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair Clin Cancer Res 12 2006 4119 4126
17. E.J. Choi Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response Mol Cancer Res 8 2010 1027 1036
18. N. Giocanti Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro Br J Cancer 91 2004 2026 2033
19. H.Q. Zhuang Radiosensitizing effects of gefitinib at different administration times in vitro Cancer Sci 100 2009 1520 1525
20. P. Chinnaiyan Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 2005 3328 3335
21. T. Tanaka Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity Clin Cancer Res 14 2008 1266 1273
22. S.M. Bokobza Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer Int J Radiat Oncol Biol Phys 88 2014 947 954
23. G.C. Chang Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells Biochem Pharmacol 68 2004 1453 1464
24. A. Di Leonardo DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts Genes Dev 8 1994 2540 2551
25. S.P. Linke, K.C. Clarkin, and G.M. Wahl P53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation Cancer Res 57 1997 1171 1179
26. K. Borgmann For X-irradiated normal human fibroblasts, only half of cell inactivation results from chromosomal damage Int J Radiat Oncol Biol Phys 58 2004 445 452
27. J. Amann Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer Cancer Res 65 2005 226 235
28. K. Gurtner Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression Radiother Oncol 99 2011 323 330
29. T. Waldman, K.W. Kinzler, and B. Vogelstein P21 is necessary for the p53-mediated G1 arrest in human cancer cells Cancer Res 55 1995 5187 5190
30. M. Wang EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks Cancer Res 71 2011 6261 6269
31. M. Kriegs The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining DNA Repair (Amst) 9 2010 889 897
32. L. Myllynen In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status Radiother Oncol 101 2011 147 151
33. H. Stegeman EGFR-inhibition enhances apoptosis in irradiated human head and neck xenograft tumors independent of effects on DNA repair Radiat Res 180 2013 414 421
34. M. Baumann, and M. Krause Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results Radiother Oncol 72 2004 257 266
35. H.R. Withers Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions Int J Radiat Oncol Biol Phys 33 1995 549 562
36. N. Stransky The mutational landscape of head and neck squamous cell carcinoma Science 333 2011 1157 1160
37. C. Van Waes Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer Int J Radiat Oncol Biol Phys 77 2010 447 454
38. R.G. Martins Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial J Clin Oncol 2013
39. J.A. Bonner Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
40. R.M. Srivastava Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients Clin Cancer Res 19 2013 1858 1872
41. C. Kandoth Mutational landscape and significance across 12 major cancer types Nature 502 2013 333 339